Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study

Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective J...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2024-12, Vol.13 (24), p.7804
Hauptverfasser: Farkas, Bernadett, Bessissow, Talat, Limdi, Jimmy K, Sethi-Arora, Karishma, Kagramanova, Anna, Knyazev, Oleg, Bezzio, Cristina, Armuzzi, Alessandro, Lukas, Milan, Michalopoulos, George, Chaskova, Elena, Savarino, Edoardo Vincenzo, Castiglione, Fabiana, Rispo, Antonio, Schäfer, Eszter, Saibeni, Simone, Filip, Rafal, Attauabi, Mohamed, Fousekis, Fotios S, Bacsur, Péter, Resál, Tamás, Bálint, Anita, Ivány, Emese, Szepes, Zoltán, Bősze, Zsófia, Fábián, Anna, Bor, Renáta, Farkas, Klaudia, Lakatos, Peter L, Molnár, Tamás
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 24
container_start_page 7804
container_title Journal of clinical medicine
container_volume 13
creator Farkas, Bernadett
Bessissow, Talat
Limdi, Jimmy K
Sethi-Arora, Karishma
Kagramanova, Anna
Knyazev, Oleg
Bezzio, Cristina
Armuzzi, Alessandro
Lukas, Milan
Michalopoulos, George
Chaskova, Elena
Savarino, Edoardo Vincenzo
Castiglione, Fabiana
Rispo, Antonio
Schäfer, Eszter
Saibeni, Simone
Filip, Rafal
Attauabi, Mohamed
Fousekis, Fotios S
Bacsur, Péter
Resál, Tamás
Bálint, Anita
Ivány, Emese
Szepes, Zoltán
Bősze, Zsófia
Fábián, Anna
Bor, Renáta
Farkas, Klaudia
Lakatos, Peter L
Molnár, Tamás
description Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] < 0.0001; p[UC] < 0.0001) and faecal calprotectin (p[CD] < 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC.
doi_str_mv 10.3390/jcm13247804
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_3149643575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A821838011</galeid><sourcerecordid>A821838011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1684-ef38d65a0824d469012b77e9e5b03ecdd7adf3c2bed0ee5f2c504bf4b1aa2b6d3</originalsourceid><addsrcrecordid>eNptUUtLxDAQLqKgqCf_QMCjVvNqm_W2rO8Hgqt4LGky0SzdZE2ywt78B579e_4SqxVUcOYww3yPgZks2yJ4j7EB3p-oKWGUVwLzpWyN4qrKMRNs-Ve_mm3GOMFdCMEpqday1xuQbX7vQ6vRkTGgkn0GBzEi6TQaSwNpgbxBY2h7DJ0PL9CZe7SNTT5EZB26axUE-QWOfGuT7cWj4B_d-8tbRIc2goxwgIboBlLwcdZ77aKreZusApcCoHGa68VGtmJkG2Hzu65nd8dHt6PT_PL65Gw0vMwVKQXPwTChy0JiQbnm5QAT2lQVDKBoMAOldSW1YYo2oDFAYagqMG8Mb4iUtCk1W8-2e99Z8E9ziKme-Hlw3cqaET4oOSuq4of1IFuorTM-BammNqp6KCgRTGBCOtbeP6wuNUyt8g6M7eZ_BDu9QHW3iAFMPQt2KsOiJrj-_GX965fsA44hkqM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149643575</pqid></control><display><type>article</type><title>Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Farkas, Bernadett ; Bessissow, Talat ; Limdi, Jimmy K ; Sethi-Arora, Karishma ; Kagramanova, Anna ; Knyazev, Oleg ; Bezzio, Cristina ; Armuzzi, Alessandro ; Lukas, Milan ; Michalopoulos, George ; Chaskova, Elena ; Savarino, Edoardo Vincenzo ; Castiglione, Fabiana ; Rispo, Antonio ; Schäfer, Eszter ; Saibeni, Simone ; Filip, Rafal ; Attauabi, Mohamed ; Fousekis, Fotios S ; Bacsur, Péter ; Resál, Tamás ; Bálint, Anita ; Ivány, Emese ; Szepes, Zoltán ; Bősze, Zsófia ; Fábián, Anna ; Bor, Renáta ; Farkas, Klaudia ; Lakatos, Peter L ; Molnár, Tamás</creator><creatorcontrib>Farkas, Bernadett ; Bessissow, Talat ; Limdi, Jimmy K ; Sethi-Arora, Karishma ; Kagramanova, Anna ; Knyazev, Oleg ; Bezzio, Cristina ; Armuzzi, Alessandro ; Lukas, Milan ; Michalopoulos, George ; Chaskova, Elena ; Savarino, Edoardo Vincenzo ; Castiglione, Fabiana ; Rispo, Antonio ; Schäfer, Eszter ; Saibeni, Simone ; Filip, Rafal ; Attauabi, Mohamed ; Fousekis, Fotios S ; Bacsur, Péter ; Resál, Tamás ; Bálint, Anita ; Ivány, Emese ; Szepes, Zoltán ; Bősze, Zsófia ; Fábián, Anna ; Bor, Renáta ; Farkas, Klaudia ; Lakatos, Peter L ; Molnár, Tamás</creatorcontrib><description>Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] &lt; 0.0001; p[UC] &lt; 0.0001) and faecal calprotectin (p[CD] &lt; 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13247804</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>C-reactive protein ; Care and treatment ; Colitis ; Crohn's disease ; Disease ; Diseases ; Drug therapy ; Ecuador ; Endoscopy ; Ethics ; Hungary ; Italy ; Kinases ; Medical research ; Medicine, Experimental ; Patient outcomes ; Patients ; Remission (Medicine) ; Russia ; Steroids ; Tofacitinib ; Ulcerative colitis</subject><ispartof>Journal of clinical medicine, 2024-12, Vol.13 (24), p.7804</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1684-ef38d65a0824d469012b77e9e5b03ecdd7adf3c2bed0ee5f2c504bf4b1aa2b6d3</cites><orcidid>0000-0002-3948-6488 ; 0000-0003-0323-7030 ; 0009-0007-8816-0138 ; 0000-0002-1454-2412 ; 0000-0002-3187-2894 ; 0000-0001-5677-2534 ; 0000-0002-3818-6205 ; 0000-0002-8534-0068 ; 0000-0003-1572-0118 ; 0000-0002-5954-151X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27915,27916</link.rule.ids></links><search><creatorcontrib>Farkas, Bernadett</creatorcontrib><creatorcontrib>Bessissow, Talat</creatorcontrib><creatorcontrib>Limdi, Jimmy K</creatorcontrib><creatorcontrib>Sethi-Arora, Karishma</creatorcontrib><creatorcontrib>Kagramanova, Anna</creatorcontrib><creatorcontrib>Knyazev, Oleg</creatorcontrib><creatorcontrib>Bezzio, Cristina</creatorcontrib><creatorcontrib>Armuzzi, Alessandro</creatorcontrib><creatorcontrib>Lukas, Milan</creatorcontrib><creatorcontrib>Michalopoulos, George</creatorcontrib><creatorcontrib>Chaskova, Elena</creatorcontrib><creatorcontrib>Savarino, Edoardo Vincenzo</creatorcontrib><creatorcontrib>Castiglione, Fabiana</creatorcontrib><creatorcontrib>Rispo, Antonio</creatorcontrib><creatorcontrib>Schäfer, Eszter</creatorcontrib><creatorcontrib>Saibeni, Simone</creatorcontrib><creatorcontrib>Filip, Rafal</creatorcontrib><creatorcontrib>Attauabi, Mohamed</creatorcontrib><creatorcontrib>Fousekis, Fotios S</creatorcontrib><creatorcontrib>Bacsur, Péter</creatorcontrib><creatorcontrib>Resál, Tamás</creatorcontrib><creatorcontrib>Bálint, Anita</creatorcontrib><creatorcontrib>Ivány, Emese</creatorcontrib><creatorcontrib>Szepes, Zoltán</creatorcontrib><creatorcontrib>Bősze, Zsófia</creatorcontrib><creatorcontrib>Fábián, Anna</creatorcontrib><creatorcontrib>Bor, Renáta</creatorcontrib><creatorcontrib>Farkas, Klaudia</creatorcontrib><creatorcontrib>Lakatos, Peter L</creatorcontrib><creatorcontrib>Molnár, Tamás</creatorcontrib><title>Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study</title><title>Journal of clinical medicine</title><description>Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] &lt; 0.0001; p[UC] &lt; 0.0001) and faecal calprotectin (p[CD] &lt; 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC.</description><subject>C-reactive protein</subject><subject>Care and treatment</subject><subject>Colitis</subject><subject>Crohn's disease</subject><subject>Disease</subject><subject>Diseases</subject><subject>Drug therapy</subject><subject>Ecuador</subject><subject>Endoscopy</subject><subject>Ethics</subject><subject>Hungary</subject><subject>Italy</subject><subject>Kinases</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Remission (Medicine)</subject><subject>Russia</subject><subject>Steroids</subject><subject>Tofacitinib</subject><subject>Ulcerative colitis</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptUUtLxDAQLqKgqCf_QMCjVvNqm_W2rO8Hgqt4LGky0SzdZE2ywt78B579e_4SqxVUcOYww3yPgZks2yJ4j7EB3p-oKWGUVwLzpWyN4qrKMRNs-Ve_mm3GOMFdCMEpqday1xuQbX7vQ6vRkTGgkn0GBzEi6TQaSwNpgbxBY2h7DJ0PL9CZe7SNTT5EZB26axUE-QWOfGuT7cWj4B_d-8tbRIc2goxwgIboBlLwcdZ77aKreZusApcCoHGa68VGtmJkG2Hzu65nd8dHt6PT_PL65Gw0vMwVKQXPwTChy0JiQbnm5QAT2lQVDKBoMAOldSW1YYo2oDFAYagqMG8Mb4iUtCk1W8-2e99Z8E9ziKme-Hlw3cqaET4oOSuq4of1IFuorTM-BammNqp6KCgRTGBCOtbeP6wuNUyt8g6M7eZ_BDu9QHW3iAFMPQt2KsOiJrj-_GX965fsA44hkqM</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Farkas, Bernadett</creator><creator>Bessissow, Talat</creator><creator>Limdi, Jimmy K</creator><creator>Sethi-Arora, Karishma</creator><creator>Kagramanova, Anna</creator><creator>Knyazev, Oleg</creator><creator>Bezzio, Cristina</creator><creator>Armuzzi, Alessandro</creator><creator>Lukas, Milan</creator><creator>Michalopoulos, George</creator><creator>Chaskova, Elena</creator><creator>Savarino, Edoardo Vincenzo</creator><creator>Castiglione, Fabiana</creator><creator>Rispo, Antonio</creator><creator>Schäfer, Eszter</creator><creator>Saibeni, Simone</creator><creator>Filip, Rafal</creator><creator>Attauabi, Mohamed</creator><creator>Fousekis, Fotios S</creator><creator>Bacsur, Péter</creator><creator>Resál, Tamás</creator><creator>Bálint, Anita</creator><creator>Ivány, Emese</creator><creator>Szepes, Zoltán</creator><creator>Bősze, Zsófia</creator><creator>Fábián, Anna</creator><creator>Bor, Renáta</creator><creator>Farkas, Klaudia</creator><creator>Lakatos, Peter L</creator><creator>Molnár, Tamás</creator><general>MDPI AG</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-3948-6488</orcidid><orcidid>https://orcid.org/0000-0003-0323-7030</orcidid><orcidid>https://orcid.org/0009-0007-8816-0138</orcidid><orcidid>https://orcid.org/0000-0002-1454-2412</orcidid><orcidid>https://orcid.org/0000-0002-3187-2894</orcidid><orcidid>https://orcid.org/0000-0001-5677-2534</orcidid><orcidid>https://orcid.org/0000-0002-3818-6205</orcidid><orcidid>https://orcid.org/0000-0002-8534-0068</orcidid><orcidid>https://orcid.org/0000-0003-1572-0118</orcidid><orcidid>https://orcid.org/0000-0002-5954-151X</orcidid></search><sort><creationdate>20241201</creationdate><title>Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study</title><author>Farkas, Bernadett ; Bessissow, Talat ; Limdi, Jimmy K ; Sethi-Arora, Karishma ; Kagramanova, Anna ; Knyazev, Oleg ; Bezzio, Cristina ; Armuzzi, Alessandro ; Lukas, Milan ; Michalopoulos, George ; Chaskova, Elena ; Savarino, Edoardo Vincenzo ; Castiglione, Fabiana ; Rispo, Antonio ; Schäfer, Eszter ; Saibeni, Simone ; Filip, Rafal ; Attauabi, Mohamed ; Fousekis, Fotios S ; Bacsur, Péter ; Resál, Tamás ; Bálint, Anita ; Ivány, Emese ; Szepes, Zoltán ; Bősze, Zsófia ; Fábián, Anna ; Bor, Renáta ; Farkas, Klaudia ; Lakatos, Peter L ; Molnár, Tamás</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1684-ef38d65a0824d469012b77e9e5b03ecdd7adf3c2bed0ee5f2c504bf4b1aa2b6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>C-reactive protein</topic><topic>Care and treatment</topic><topic>Colitis</topic><topic>Crohn's disease</topic><topic>Disease</topic><topic>Diseases</topic><topic>Drug therapy</topic><topic>Ecuador</topic><topic>Endoscopy</topic><topic>Ethics</topic><topic>Hungary</topic><topic>Italy</topic><topic>Kinases</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Remission (Medicine)</topic><topic>Russia</topic><topic>Steroids</topic><topic>Tofacitinib</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farkas, Bernadett</creatorcontrib><creatorcontrib>Bessissow, Talat</creatorcontrib><creatorcontrib>Limdi, Jimmy K</creatorcontrib><creatorcontrib>Sethi-Arora, Karishma</creatorcontrib><creatorcontrib>Kagramanova, Anna</creatorcontrib><creatorcontrib>Knyazev, Oleg</creatorcontrib><creatorcontrib>Bezzio, Cristina</creatorcontrib><creatorcontrib>Armuzzi, Alessandro</creatorcontrib><creatorcontrib>Lukas, Milan</creatorcontrib><creatorcontrib>Michalopoulos, George</creatorcontrib><creatorcontrib>Chaskova, Elena</creatorcontrib><creatorcontrib>Savarino, Edoardo Vincenzo</creatorcontrib><creatorcontrib>Castiglione, Fabiana</creatorcontrib><creatorcontrib>Rispo, Antonio</creatorcontrib><creatorcontrib>Schäfer, Eszter</creatorcontrib><creatorcontrib>Saibeni, Simone</creatorcontrib><creatorcontrib>Filip, Rafal</creatorcontrib><creatorcontrib>Attauabi, Mohamed</creatorcontrib><creatorcontrib>Fousekis, Fotios S</creatorcontrib><creatorcontrib>Bacsur, Péter</creatorcontrib><creatorcontrib>Resál, Tamás</creatorcontrib><creatorcontrib>Bálint, Anita</creatorcontrib><creatorcontrib>Ivány, Emese</creatorcontrib><creatorcontrib>Szepes, Zoltán</creatorcontrib><creatorcontrib>Bősze, Zsófia</creatorcontrib><creatorcontrib>Fábián, Anna</creatorcontrib><creatorcontrib>Bor, Renáta</creatorcontrib><creatorcontrib>Farkas, Klaudia</creatorcontrib><creatorcontrib>Lakatos, Peter L</creatorcontrib><creatorcontrib>Molnár, Tamás</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farkas, Bernadett</au><au>Bessissow, Talat</au><au>Limdi, Jimmy K</au><au>Sethi-Arora, Karishma</au><au>Kagramanova, Anna</au><au>Knyazev, Oleg</au><au>Bezzio, Cristina</au><au>Armuzzi, Alessandro</au><au>Lukas, Milan</au><au>Michalopoulos, George</au><au>Chaskova, Elena</au><au>Savarino, Edoardo Vincenzo</au><au>Castiglione, Fabiana</au><au>Rispo, Antonio</au><au>Schäfer, Eszter</au><au>Saibeni, Simone</au><au>Filip, Rafal</au><au>Attauabi, Mohamed</au><au>Fousekis, Fotios S</au><au>Bacsur, Péter</au><au>Resál, Tamás</au><au>Bálint, Anita</au><au>Ivány, Emese</au><au>Szepes, Zoltán</au><au>Bősze, Zsófia</au><au>Fábián, Anna</au><au>Bor, Renáta</au><au>Farkas, Klaudia</au><au>Lakatos, Peter L</au><au>Molnár, Tamás</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study</atitle><jtitle>Journal of clinical medicine</jtitle><date>2024-12-01</date><risdate>2024</risdate><volume>13</volume><issue>24</issue><spage>7804</spage><pages>7804-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] &lt; 0.0001; p[UC] &lt; 0.0001) and faecal calprotectin (p[CD] &lt; 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/jcm13247804</doi><orcidid>https://orcid.org/0000-0002-3948-6488</orcidid><orcidid>https://orcid.org/0000-0003-0323-7030</orcidid><orcidid>https://orcid.org/0009-0007-8816-0138</orcidid><orcidid>https://orcid.org/0000-0002-1454-2412</orcidid><orcidid>https://orcid.org/0000-0002-3187-2894</orcidid><orcidid>https://orcid.org/0000-0001-5677-2534</orcidid><orcidid>https://orcid.org/0000-0002-3818-6205</orcidid><orcidid>https://orcid.org/0000-0002-8534-0068</orcidid><orcidid>https://orcid.org/0000-0003-1572-0118</orcidid><orcidid>https://orcid.org/0000-0002-5954-151X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof Journal of clinical medicine, 2024-12, Vol.13 (24), p.7804
issn 2077-0383
2077-0383
language eng
recordid cdi_proquest_journals_3149643575
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central
subjects C-reactive protein
Care and treatment
Colitis
Crohn's disease
Disease
Diseases
Drug therapy
Ecuador
Endoscopy
Ethics
Hungary
Italy
Kinases
Medical research
Medicine, Experimental
Patient outcomes
Patients
Remission (Medicine)
Russia
Steroids
Tofacitinib
Ulcerative colitis
title Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T06%3A38%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-World%20Effectiveness%20and%20Safety%20of%20Selective%20JAK%20Inhibitors%20in%20Ulcerative%20Colitis%20and%20Crohn%E2%80%99s%20Disease:%20A%20Retrospective,%20Multicentre%20Study&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Farkas,%20Bernadett&rft.date=2024-12-01&rft.volume=13&rft.issue=24&rft.spage=7804&rft.pages=7804-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13247804&rft_dat=%3Cgale_proqu%3EA821838011%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3149643575&rft_id=info:pmid/&rft_galeid=A821838011&rfr_iscdi=true